In this issue:
Leukaemia selection
Prognostic impact of MRD in first-line therapy for CLL
Bone marrow MRD eradication and therapy discontinuation in CLL
Idelalisib and rituximab in relapsed CLL
Resistance mechanisms for ibrutinib
Lymphoma selection
ALC/AMC ratio predicts outcomes in DLBCL after standard first-line regimens
Objective responses in relapsed T-cell lymphomas with brentuximab
High- vs. standard dose CEOP + filgrastim in non-Hodgkin’s lymphoma
Allogeneic stem-cell transplant for advanced cutaneous T-cell lymphomas
Pharmacokinetics and safety of SC rituximab in FL
Rituximab vs. watchful waiting in advanced-stage FL
Please login below to download this issue (PDF)